TrovaGene acquires the CLIA certified molecular diagnostic laboratory business (or operations) from MultiGen Diagnostics, a privately held biotechnology company located in San Diego, CA.
Feb 8, 2012
Trovagene Closes Acquisition of CLIA Laboratory Assets
Jan 17, 2012
TrovaGene Presentation [8k]: Introduction to TrovaGene
Jan 6, 2012
TrovaGene Acquires CLIA - Certified Laboratory
Jan 3, 2012
TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
World-Leading Research
TrovaGene develops novel diagnostic methods and markers based around it’s analysis of DNA fragments from urine.
Fully Integrated Platform
TrovaGene offers a complete integrated molecular diagnostics CLIA service, backed by our strength in basic research into novel diagnostics and markers
Diagnostic Markers for Chronic Lymphocytic Leukemia (CLL)
Find out more about our exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia (CLL)
Unique Diagnostic Technology
Our revolutionary urine-based detection of molecular signals originating from localized or systemic conditions is changing the way that disease is detected
TrovaGene, INC. | TROV.PK
© TrovaGene 2012 | TrovaGene Inc. | TrovaGene Inc. | 11055 Flintkote Ave., Suite B | San Diego | CA 92121 | info@TrovaGene.com | Tel.: USA [+1] 858 217 4838
